{"prompt": "['Product: MK-3475', '87', 'Protocol/Amendment No.: 604-09', 'The EQ-5D-5L, EORTC QLQ-C30, and EORTC QLQ-LC13 are completed every cycle for', 'Cycles 1 to 9, then every other cycle up to Cycle 17 (ie, Cycles 11, 13, 15, and 17) while the', 'subject is receiving study treatment. Patient-reported outcomes will also be obtained at the', 'treatment discontinuation visit and 30-day Safety Follow-up visit.', '7.1.3.3 Planned Genetic Analysis Sample Collection', 'Sample collection, storage and shipment instructions for Planned Genetic Analysis samples', 'will be provided in the Laboratory Manual.', '7.1.3.4 Future Biomedical Research Samples', 'The following specimens are to be obtained as part of Future Biomedical Research:', 'DNA for future research', 'Leftover RNA', 'Leftover plasma and serum from biomarker analyses', 'Leftover tumor', '7.1.4', 'Other Procedures', '7.1.4.1 Withdrawal/Discontinuation', 'Subjects who discontinue treatment prior to completion of the treatment regimen should be', 'encouraged to continue to be followed for all remaining study visits.', 'When a subject discontinues/withdraws from participation in the trial, all applicable activities', 'scheduled for the final trial visit should be performed at the time of discontinuation. Any', 'adverse events which are present at the time of discontinuation/withdrawal should be', 'followed in accordance with the safety requirements outlined in Section 7.2 - Assessing and', 'Recording Adverse Events.', 'Withdrawal From Future Biomedical Research', 'Subjects may withdraw their consent for Future Biomedical Research. Subjects may', 'withdraw consent at any time by contacting the principal investigator for the main trial. If', 'medical records for the main trial are still available, the investigator will contact the Sponsor', 'using the designated mailbox (clinical.specimen.management@merck.com). Subsequently,', \"the subject's consent for Future Biomedical Research will be withdrawn. A letter will be sent\", 'from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the', 'investigator to inform the subject of completion of withdrawal. Any analyses in progress at', 'the time of request for withdrawal or already performed prior to the request being received', 'by the Sponsor will continue to be used as part of the overall research trial data and results.', 'No new analyses would be generated after the request is received.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '88', 'Protocol/Amendment No.: 604-09', 'In the event that the medical records for the main trial are no longer available (e.g., if the', 'investigator is no longer required by regulatory authorities to retain the main trial records) or', 'the specimens have been completely anonymized, there will no longer be a link between the', \"subject's personal information and their specimens. In this situation, the request for\", 'specimen withdrawal cannot be processed.', '7.1.4.2 Subject Blinding/Unblinding', 'When the investigator or delegate needs to identify the drug used by a subject and the dosage', 'administered in case of emergency e.g., the occurrence of serious adverse events, he/she will', 'contact the emergency unblinding call center by telephone and make a request for emergency', 'unblinding. As requested by the investigator or delegate the emergency unblinding call', 'center will provide the information to him/her promptly and report unblinding to the Sponsor.', \"Prior to contacting the emergency unblinding call center to request unblinding of a subject's\", 'treatment assignment, the investigator or delegate must enter the toxicity grade of the adverse', 'events observed, the relation to study drug, the reason thereof, etc., in the medical chart etc.', 'Subjects whose treatment assignment has been unblinded by the investigator/delegate and/or', 'non-study treating physician must be discontinued from study drug, but should continue to be', 'monitored in the trial.', 'Treatment identification information is to be unmasked ONLY if necessary for the welfare of', 'the subject. Every effort should be made not to unblind the subject unless necessary.', 'In the event that unblinding has occurred, the circumstances around the unblinding (eg, date,', 'reason and person performing the unblinding) must be documented promptly, and the', 'Sponsor Clinical Director notified as soon as possible. Once an emergency unblinding or a', 'non-emergency unblinding has taken place, the principal investigator, site personnel, and', 'Sponsor personnel may be unblinded so that the appropriate follow-up medical care can be', 'provided to the subject.', '7.1.4.3 Calibration of Critical Equipment', 'The investigator or qualified designee has the responsibility to ensure that any critical device', 'or instrument used for a clinical evaluation/test during a clinical trial that provides important', 'information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be', 'suitably calibrated and maintained to ensure that the data obtained is reliable and/or', 'reproducible. Documentation of equipment calibration must be retained as source', 'documentation at the trial site.', 'Critical Equipment for this trial includes:', 'None', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}